PGEN compared with NVCT: revenue, margins and what each company keeps, and the suppliers and customers both name

PGENPrecigen, Inc.

Mkt capRevenueRevenue

NVCTNuvectis Pharma, Inc.

Mkt capRevenueRevenue

Compare

PGENPrecigen, Inc.

NVCTNuvectis Pharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

NVCT: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PGEN 8

PTCTPTC Therapeuticscustomer

—University of Texas MD Anderson Cancer Centerunlistedsupplier

—Eversanaunlistedsupplier

—National Cancer Institute (NCI)unlistedsupplier

4 more · PGEN chain ›

Shared 0

No shared counterparties.

Only NVCT 4

—CRT Pioneer Fundunlistedsupplier

—ICRunlistedsupplier

—University of Edinburghunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

UoE

unlistedsupplier

Price

rebased to 0%

PGEN, solidNVCT, dashed

PGENPrecigen, Inc.

6.94· pre 5.57

Mkt cap$2.5BRevenue$55MQ2 FY26Revenue$10MFY25

NVCTNuvectis Pharma, Inc.

18.38· pre 18.99· delayed

Pre-marketSep 2 '83

Mkt cap$602.1MRevenue—Revenue—

Compare

Pre-marketSep 2 '83

PGENPrecigen, Inc.

NVCTNuvectis Pharma, Inc.

6.94pre 5.57

Price

18.38pre 18.99delayed

$2.5B

Mkt cap

$602.1M

Q2 FY26$55M

Revenue

—

FY25$10M

Revenue

—

PGEN6.94vsNVCT18.38Pre-marketSep 2 '83